Kriya Therapeutics vs Karius
Side-by-side comparison of AI visibility scores, market position, and capabilities
Kriya Therapeutics is a gene therapy company using AAV vector engineering to develop one-time treatments for chronic diseases including diabetes and hemophilia; raised $270M total including a $150M Series C in 2022 led by Premji Invest;
About
Kriya Therapeutics is a gene therapy company founded in 2019 by Saket Bhargava and Chintan Shah, headquartered in Research Triangle Park, North Carolina. The company is building a platform for adeno-associated virus (AAV) gene therapy specifically targeting chronic metabolic and cardiovascular diseases — conditions where a single gene therapy treatment could potentially replace a lifetime of injectable or oral medications. Kriya's therapeutic thesis is that gene therapy, historically applied to rare genetic diseases, can be extended to larger-prevalence conditions like type 2 diabetes, obesity, and lipid disorders — unlocking much larger commercial markets than orphan drug gene therapy programs.
Karius raised $409M total including a $100M Series C in May 2024; its genomic blood test detects 1,000+ pathogens at 400+ U.S. hospitals; launched Karius Focus BAL for pneumonia in April 2025.
About
Karius is a Redwood City, CA-based life sciences company founded in 2014 that developed the Karius Test — a single blood draw that uses next-generation sequencing and AI to detect over 1,000 pathogens (bacteria, fungi, viruses, parasites) in seriously ill patients. The test is used when conventional cultures and targeted diagnostics fail, providing clinicians at transplant centers, children''s hospitals, and ICUs with a comprehensive pathogen report within 24 hours.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.